Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
Peking University Third Hospital
50 participants
Dec 15, 2023
INTERVENTIONAL
Conditions
Summary
FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.
Eligibility
Inclusion Criteria3
- Age ≥ 18 years;
- Patients diagnosed with TED;
- Complete understanding and voluntary participation in this study, with the signing of an informed consent form.
Exclusion Criteria5
- Severe liver or kidney dysfunction;
- Inability to maintain a supine position for 5 minutes to cooperate with the examination;
- Suffering from claustrophobia or other psychiatric disorders;
- Patients planning pregnancy or in the prenatal or lactation period;
- Other conditions deemed unsuitable for participation in the trial by the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06359795